Scout Bio, a Philadelphia company developing gene therapies for animal health, has licensed a new kind of technology from the Penn’s gene therapy program.
Passage Bio has exercised two additional options for potential new drug candidates under its research collaboration with Penn's gene therapy program.
In experiments using saliva samples from COVID-19 patients, the gum, which contains the ACE2 protein, neutralized the virus, according to research led by School of Dental Medicine scientists.
The event honors the patent recipients from the previous fiscal year, as well as, those partners, inventors, and startups that made exceptional achievements.
Carter Caldwell, the Director of the Penn Medicine Co-Investment Program, wrote a guest blog for Penn Medicine News on how the University has impacted his life as a student, a patient, and an employee
Center brings together autoimmune disease researchers and clinicians to advance diagnosis and treatment
President Amy Gutmann has announced the launch of a $750 million investment.
At Penn, a leader in GBM cellular therapies since the early days of this technology, a new CAR cell therapy could find its way into clinical trials by next year in collaboration with Tmunity.
Webinar hosted by the Penn Center for Innovation with Dr. Kathryn Doyle, Partner, Saul Ewing Arnstein & Lehr.
Katherine Reuther, Ph.D., MBA, Executive Director of the Penn Center for Health-Devices and Technology discusses resources to support your medical device idea.